Cutanea Life Sciences, Inc. · Malvern, PA United States (NASDAQ: CTNA)
| 5 Great Valley Pkwy, Ste. 355 | Phone: 484-568-0100 |
| Malvern, PA | Fax: 484-568-0101 |
| 19355 | |
| United States | 
Map This Company |
Cutanea Life Sciences, Inc. Rankings
Company Description
Cutanea Life Sciences knows skin conditions aren't exactly cute. That's why the pharmaceutical company in-licenses and develops therapies for the treatment of dermatological disorders. Lead candidate omiganan, a chemical entity with anti-microbial and anti-inflammatory properties, is being clinically studied to treat rosacea, which causes persistent redness and sometimes lesions on the face. Other studies are testing omiganan's effectiveness against atopic dermatitis, a type of eczema. Additional candidates in its portfolio include a dermal filler to treat fine lines and wrinkles and a topical product for non-genital warts caused by human papillomavirus (HPV). Cutanea Life Sciences filed to go public in mid-2010.
Cutanea Life Sciences, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Private - NASDAQ: CTNA Single Location |
|---|---|
| Fiscal Year-End | December |
| 2009 Employees | 2 |
Executives
10 executives listed for Cutanea Life Sciences, Inc.'s Malvern, PA location.
| President, CEO, and Director | Robert Bitterman | |
|---|---|---|
| Interim CFO | James McMonagle | |
| EVP and Chief Scientific Officer | Kimberley Forbes-McKean |